Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CS DiagnosticsCSDX ROE % is 0.03% as of Dec. 2025, which is 200% above its 10-year median of 0.01. The stock has 1 warning sign investors should review. Among 798 Medical Devices & Instruments companies, CS Diagnostics ranks worse than 55.39% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. CS Diagnostics's annualized net income for the quarter that ended in Dec. 2025 was $0.16 Mil. CS Diagnostics's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $499.45 Mil. Therefore, CS Diagnostics's annualized ROE % for the quarter that ended in Dec. 2025 was 0.03%.
The historical rank and industry rank for CS Diagnostics's ROE % or its related term are showing as below:
CSDX'
s ROE % Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.01
Current: 0.01
During the past 7 years, CS Diagnostics's highest ROE % was 0.01%. The lowest was 0.01%. And the median was 0.01%.
CSDX's ROE % is ranked worse than 55.39% of 798
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs CSDX: 0.01
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
CS Diagnostics ROE % Related Terms
CS Diagnostics ROE % Historical Data
* Premium members only.
The historical data trend for CS Diagnostics's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CS Diagnostics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CS Diagnostics ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CS Diagnostics's ROE % distribution charts can be found below:
* The bar in red indicates where CS Diagnostics's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
CS Diagnostics (CSDX) has a ROE % of 0.03% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CS Diagnostics and its competitors. This is 200% above median its historical median of 0.01. Over the past decade, CS Diagnostics' ROE % has ranged from 0.01 to 0.01. According to the industry distribution chart, CS Diagnostics ranks #442 out of 798 companies in the Medical Devices & Instruments industry, placing it in the top 55.4%.
Is CS Diagnostics' ROE % too high?
CS Diagnostics' current ROE % of 0.03% is 200% above median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.01. The Medical Devices & Instruments industry median ROE % is 2.43. CS Diagnostics' value of 0.03% is 98.8% below this industry median. Based on the distribution chart, CS Diagnostics ranks #442 out of 798 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does CS Diagnostics' ROE % compare to NMTC and IRIX?
According to the Medical Devices & Instruments industry distribution chart, CS Diagnostics ranks #442 out of 798 companies for ROE %. This places CS Diagnostics in the lower half of its industry. The industry median ROE % is 2.43. CS Diagnostics' value of 0.03% is 98.8% below this benchmark. Historically, CS Diagnostics' own ROE % has ranged from 0.01 to 0.01 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 2.43, CS Diagnostics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.43, based on 798 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CS Diagnostics's current ROE % of 0.03% is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on CS Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CS Diagnostics's current ROE % is 0.03%, which is 200% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CS Diagnostics stock overvalued right now?
CS Diagnostics (CSDX) has a current ROE % of 0.03%. The current ROE % is 0.03%, which is 200% above median its 10-year median of 0.01 and 98.8% below the Medical Devices & Instruments industry median of 2.43. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For CS Diagnostics (CSDX), the current ROE % is 0.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CS Diagnostics Corp is a United States based Corporation, its focus is on improving therapy results and reducing side effects. In addition, it offers international companies in the medical industry access to markets and the service of approval of medical products in Europe and the MENA regions. Furthermore, it develops its own products with the aim of maximizing patient benefit.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSDX has been successfully added to your 
